COMBINATION MEDICINE OF TEMOZOLOMIDE AND MUTANT IDH1 ENZYME INHIBITOR
To provide combination medicines with excellent effects on cancers with IDH1 gene mutations that can reduce the dose of temozolomide without reducing the antitumor effect.SOLUTION: The present invention is completed by finding that the combination of temozolomide and a mutant IDH1 enzyme inhibitor c...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Patent |
Sprache: | eng ; jpn |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | SEKI TAKEHIKO |
description | To provide combination medicines with excellent effects on cancers with IDH1 gene mutations that can reduce the dose of temozolomide without reducing the antitumor effect.SOLUTION: The present invention is completed by finding that the combination of temozolomide and a mutant IDH1 enzyme inhibitor can reduce the dose of temozolomide without reducing the antitumor effect.SELECTED DRAWING: None
【課題】 本発明の課題は、抗腫瘍作用を低下させずにテモゾロミドの投与量を削減することができる、IDH1遺伝子変異を有するがんに対して優れた効果を有する組み合わせ医薬を提供することである。【解決手段】 テモゾロミドと変異型IDH1酵素阻害剤を組み合わせることで、抗腫瘍作用を低下させずにテモゾロミドの投与量を削減することができることを見出し、本発明を完成するに至った。【選択図】 なし |
format | Patent |
fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_JP2022021331A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>JP2022021331A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_JP2022021331A3</originalsourceid><addsrcrecordid>eNqNyrEKwjAQgOEsDqK-w-EumOYJ0uRKTrw7kXOwSykSJ9FCfX908AGEH77lXzpMyi1JNFIBxkyJBEE7MGTt9ahMGSFKBr5YFAPKxQNKf2UEkkItmZ7XbnEfH3Pd_Fy5bYeWyq5Or6HO03irz_oeDqdm33zzIfgY_po-0lYsUA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>COMBINATION MEDICINE OF TEMOZOLOMIDE AND MUTANT IDH1 ENZYME INHIBITOR</title><source>esp@cenet</source><creator>SEKI TAKEHIKO</creator><creatorcontrib>SEKI TAKEHIKO</creatorcontrib><description>To provide combination medicines with excellent effects on cancers with IDH1 gene mutations that can reduce the dose of temozolomide without reducing the antitumor effect.SOLUTION: The present invention is completed by finding that the combination of temozolomide and a mutant IDH1 enzyme inhibitor can reduce the dose of temozolomide without reducing the antitumor effect.SELECTED DRAWING: None
【課題】 本発明の課題は、抗腫瘍作用を低下させずにテモゾロミドの投与量を削減することができる、IDH1遺伝子変異を有するがんに対して優れた効果を有する組み合わせ医薬を提供することである。【解決手段】 テモゾロミドと変異型IDH1酵素阻害剤を組み合わせることで、抗腫瘍作用を低下させずにテモゾロミドの投与量を削減することができることを見出し、本発明を完成するに至った。【選択図】 なし</description><language>eng ; jpn</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220202&DB=EPODOC&CC=JP&NR=2022021331A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220202&DB=EPODOC&CC=JP&NR=2022021331A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SEKI TAKEHIKO</creatorcontrib><title>COMBINATION MEDICINE OF TEMOZOLOMIDE AND MUTANT IDH1 ENZYME INHIBITOR</title><description>To provide combination medicines with excellent effects on cancers with IDH1 gene mutations that can reduce the dose of temozolomide without reducing the antitumor effect.SOLUTION: The present invention is completed by finding that the combination of temozolomide and a mutant IDH1 enzyme inhibitor can reduce the dose of temozolomide without reducing the antitumor effect.SELECTED DRAWING: None
【課題】 本発明の課題は、抗腫瘍作用を低下させずにテモゾロミドの投与量を削減することができる、IDH1遺伝子変異を有するがんに対して優れた効果を有する組み合わせ医薬を提供することである。【解決手段】 テモゾロミドと変異型IDH1酵素阻害剤を組み合わせることで、抗腫瘍作用を低下させずにテモゾロミドの投与量を削減することができることを見出し、本発明を完成するに至った。【選択図】 なし</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNyrEKwjAQgOEsDqK-w-EumOYJ0uRKTrw7kXOwSykSJ9FCfX908AGEH77lXzpMyi1JNFIBxkyJBEE7MGTt9ahMGSFKBr5YFAPKxQNKf2UEkkItmZ7XbnEfH3Pd_Fy5bYeWyq5Or6HO03irz_oeDqdm33zzIfgY_po-0lYsUA</recordid><startdate>20220202</startdate><enddate>20220202</enddate><creator>SEKI TAKEHIKO</creator><scope>EVB</scope></search><sort><creationdate>20220202</creationdate><title>COMBINATION MEDICINE OF TEMOZOLOMIDE AND MUTANT IDH1 ENZYME INHIBITOR</title><author>SEKI TAKEHIKO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_JP2022021331A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; jpn</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SEKI TAKEHIKO</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SEKI TAKEHIKO</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>COMBINATION MEDICINE OF TEMOZOLOMIDE AND MUTANT IDH1 ENZYME INHIBITOR</title><date>2022-02-02</date><risdate>2022</risdate><abstract>To provide combination medicines with excellent effects on cancers with IDH1 gene mutations that can reduce the dose of temozolomide without reducing the antitumor effect.SOLUTION: The present invention is completed by finding that the combination of temozolomide and a mutant IDH1 enzyme inhibitor can reduce the dose of temozolomide without reducing the antitumor effect.SELECTED DRAWING: None
【課題】 本発明の課題は、抗腫瘍作用を低下させずにテモゾロミドの投与量を削減することができる、IDH1遺伝子変異を有するがんに対して優れた効果を有する組み合わせ医薬を提供することである。【解決手段】 テモゾロミドと変異型IDH1酵素阻害剤を組み合わせることで、抗腫瘍作用を低下させずにテモゾロミドの投与量を削減することができることを見出し、本発明を完成するに至った。【選択図】 なし</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng ; jpn |
recordid | cdi_epo_espacenet_JP2022021331A |
source | esp@cenet |
subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
title | COMBINATION MEDICINE OF TEMOZOLOMIDE AND MUTANT IDH1 ENZYME INHIBITOR |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T05%3A31%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SEKI%20TAKEHIKO&rft.date=2022-02-02&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EJP2022021331A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |